ongkankernet implementation ctDNA Analysis

Completed

• Conditions: Lung cancer; non-small cell lung cancer; 10038666

• Registration Number: NL-OMON50777
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 250

Inclusion Criteria

• Patients with confirmed or suspected non-small cell lung cancer
• Signed informed consent
• Adult (>= 18 years of age) and mentally competent

Exclusion Criteria

• Patients with a benign lesion
• Patients with a metastasis of another primary cancer than lung cancer

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary aim of this study is to implement the ctDNA analysis to identify<br /><br>actionable targets in lung tumors.<br /><br><br /><br>We envision this study will create awareness in regional hospitals with this<br /><br>novel test method. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Percentage of patients identified as having an activating and targetable<br /><br>genetic alteration as determined by tissue and liquid biopsies with an<br /><br>intra-individual comparison of the presence of driver mutations detected in<br /><br>tissue and liquid biopsies.<br /><br><br /><br>2. To get insight in the time it takes from diangosis to start of targeted<br /><br>treatment.<br /><br><br /><br>3. The percentage of patient with inadequate tissue for analysis where ctDNA<br /><br>may be an alternative.<br /><br><br /><br>4. Exploring cost- effectiveness</p><br>